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SarcopeniaWith the extension of life span over the past several decades, the age-related loss of muscle mass and
strength that characterizes sarcopenia is becoming more evident and thus, has a more signiﬁcant impact
on society. To determine ways to intervene and delay, or even arrest the physical frailty and dependence
that accompany sarcopenia, it is necessary to identify those biochemical pathways that deﬁne this process.
Animal models that mimic one or more of the physiological pathways involved with this phenomenon are
very beneﬁcial in providing an understanding of the cellular processes at work in sarcopenia. The ability to
inﬂuence pathways through genetic manipulation gives insight into cellular responses and their impact on
the physical expression of sarcopenia. This review evaluates several murine models that have the potential
to elucidate biochemical processes integral to sarcopenia. Identifying animal models that reﬂect sarcopenia
or its component pathways will enable researchers to better understand those pathways that contribute to
age-related skeletal muscle mass loss, and in turn, develop interventions that will prevent, retard, arrest, or
reverse this phenomenon. This article is part of a Special Issue entitled: Animal Models of Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
During development skeletal muscle ﬁbers grow in size and
number, manifesting increased overall size and strength in the
organism. Muscle ﬁbers decrease in size and/or number with age,
disuse, and disease. As muscle ﬁber number and size decrease
there is a corresponding decrease in the ability of the muscle to
generate force. Muscle force demonstrated is commonly termed
strength. In the case of muscle atrophy as a result of disuse, muscle
ﬁber size can be restored over time with active exercise. Strength
loss in those experiencing cachexia (wasting accompanying dis-
ease) or sarcopenia (muscle mass loss accompanying aging) is es-
pecially problematic, as ﬁber size and strength are not so easily
recovered, producing frailty which tends to spiral into greater de-
pendence and increased falls in the aged and chronically ill. The
ever-increasing life span without an accompanying increase in
health span in humans leads to larger populations experiencing
sarcopenia and cachexia. With all these considerations, sarcopenic
and cachectic frailty imposes a considerable ﬁnancial burden on
the healthcare system as well as greater stress on individual fami-
lies, and a decreased quality of life of the individuals affected.l Models of Disease.
y, Physiology and Therapeutics,
Sciences, 501 N. Columbia Rd.,
: +1 701 777 4490.
. Brown-Borg).
l rights reserved.Although sarcopenia is considered a natural consequence of
aging, studies have demonstrated that the process can be slowed,
and there is research that suggests that the process can be stopped
and even reversed [1].
Although atrophy, cachexia, and sarcopenia share a common trait
in loss of muscle mass, there are distinct differences in their wasting
outcomes as well as in the biochemical processes that promote them.
Sarcopenia (a term reserved for the atrophy that accompanies the
physiological process of aging) [2], is characterized by a loss in
both ﬁber size and number [3] with ﬁber type II transitioning to
type I [4,5]. In contrast, in disuse atrophy, ﬁber size is decreased yet
ﬁber number is maintained [6] with a tendency of type I ﬁbers
transitioning to type II [7,8]. Wasting in cachexia involves both adi-
pose tissue and skeletal muscle tissue [9], with cachexia targeting
ﬁber types depending on the pathology. Muscle wasting from cancer
is primarily directed toward type II ﬁbers [10], while congestive
heart failure tends to degrade type I or type IIA contractile proteins
[11,12]. Atrophy and weakness are generated in each of these condi-
tions (aging, disuse and cachexia), yet each is difﬁcult to separate
mechanistically because of overlapping signaling systems. Mecha-
nisms of sarcopenia will be addressed in this paper with allusions
made to cachexia and disuse atrophy when appropriate.
The identiﬁcation of appropriate animal models and the path-
ways to arrest or even reverse the process of ﬁber loss and atrophy,
will provide a better understanding of the sarcopenia pathways. This
greater understanding is critical to increase health span by delaying
the onset of frailty in the presence of aging.
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Skeletal muscle is a postmitotic tissue, arriving at its ﬁnal number
of cells (the muscle ﬁbers), early in life, after which changes in
muscle size are dependent on the change in individual ﬁber size.
Satellite cells, most likely, account for the increased DNA content
observed in muscle tissues during development [13–15]. Cells can
elongate and increase girth through the addition of sarcomeres [14]
and myoﬁbrils [13], respectively; however, muscle ﬁber number
stays constant into adulthood, At this point, ﬁber number and size
decline from the early 3rd decade [3,16] through senescence, such
that muscle mass declines from 50% of total body weight to 25%
[17,18]. Muscle cells can repair or replace damaged muscle ﬁbers
when stress (e.g., exercise or trauma) activates the neighboring
quiescent satellite cells, causing them to proliferate, migrate, and
replace/repair the injured myoﬁbers [19].
There are several pathways involved in the process of muscle
loss (Fig. 1). Its course involves an imbalance between anabolism
and catabolism, with protein loss ultimately the stronger inﬂu-
ence [20]. Endocrine and inﬂammatory factors are the general
mediators of this balance [21]. Negative regulators of skeletal
muscle mass that could play a role in sarcopenia include the
endosome–lysosome, Ca2+-dependent, caspase-dependent, and
ubiquitin/proteasome-dependent pathways [22]. Protein synthe-
sis in skeletal muscle is driven by growth hormone, IGF-1 [23], in-
sulin, and testosterone [20] being undergirded by adequate
nutrition and exercise [24].
2.1. PI3K/Akt pathway
One of the central pathways to muscle size control is the PI3K/Akt
pathway, a pathway modulated by IGF-1 and insulin [25]. Stimula-
tion of protein synthesis and hypertrophy involves these hormones
interacting with their respective tyrosine kinase receptors to phos-
phorylate IRS (insulin receptor substrate)-1 and activate PI3K/Akt
(phosphatidylinositol-3-kinase/protein kinase B) signaling [26],
that activates mTOR (mammalian target of rapamycin) [27], and in
turn, phosphorylates the targets p70S6K (ribosomal p70 S6 kinase)
and 4E-BP1 (4E-binding protein) [28,29]. The activation of Akt si-
multaneously resists atrophy by phosphorylating FoxO transcription
factors, preventing translocation to the nucleus where they would
otherwise promote transcription of atrophy-related genes MuRF1
(muscle ring ﬁnger 1) and MAFbx (muscle atrophy F-box [also
known as atrogin-1]) [30], both of which are ubiquitin ligases that
degrade proteins [31]. Inhibition of Akt phosphorylation promotes
muscle atrophy, preventing the phosphorylation of FoxO transcrip-
tion factors, and drives the transcription of MuRF1 and MAFbx atro-
phy genes [30,32]. These genes can also be activated through a
pathway independent from Akt signaling, the NF-κB pathway men-
tioned below.
2.2. NF-κB pathway
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B
cells) is a transcription factor that is elevated in disuse atrophy [33]
and cachectic conditions [34,35] but not typically in sarcopenia
[22,36,37]. Cytokines activate NF-κB, its translocation to the nucleus
where it can then bind to the MuRF1 promoter, and initiate
proteasome-induced muscle degradation [38]. In muscle wasting of
cachexia, TNF-α often activates NF-κB by activating IKK (IκB kinase),
which then phosphorylates and degrades the NF-κB inhibitor pro-
tein, Iκ-Bα [39]. However, in disuse atrophy the NF-κB pathway
still involves IKK activation, yet it is triggered by an alternative path-
waywithout elevation of inﬂammatory cytokines [33]. At the nuclear
level, the atrophy of cachexia proceeds with the nuclear entry of p50
and p65 heterodimers from IκB degradation, while disuse atrophy ischaracterized by binding of a p50 homodimer to Bcl-3 (B cell lym-
phoma 3) in the nucleus [40,41].
2.3. Myostatin pathway
Myostatin is a negative regulator of muscle growth [42], activat-
ing and phosphorylating Smad2/3 transcription factors [43,44] by
way of the Activin IIB membrane receptor [45], and modulating the
transcription of genes, e.g., MyoD [44]. Although the IGF-I/PI3K/Akt
pathway inhibits myostatin-dependent signaling, it has been sug-
gested that the myostatin–Smad pathway inhibits Akt in its promo-
tion of protein synthesis [46]. Myostatin levels increase alongside
muscle atrophy in disuse and cachexia situations. In older animals
myostatin levels are relatively unchanged, although inhibiting
myostatin has produced ﬁber size and muscle mass gains [47,48].
2.4. Apoptosis
Apoptosis, the process of programmed cell death, in contrast to ne-
crosis [49], contributes to both sarcopenia and cachexia [50]. Apoptosis
is unique inmuscle ﬁbers in thatmuscle ﬁbers are multi-nucleated, and
therefore loss of some nuclei does not necessarily result in the destruc-
tion of the muscle ﬁber [51]. Apoptosis appears to play a role in disuse
atrophy; however, the typical apoptotic events (such as involvement
of various proteolytic caspases) vary depending on the experimental
models used [52,53]. The extent towhich apoptosis is involvedwith dis-
use atrophy is unknown beyond the relatively short term (14 days) of
the disuse in the above studies. There is some evidence in the 14-day
unloading model that the apoptotic process changes to a more
anti-apoptotic process as time progresses to limit themass loss [54]. Re-
active oxygen species are associated with immobilization [55] and
unloading [56] atrophy and can directly activate NF-κB without the in-
ﬂuence of TNF-α [57]. In the case of cachexia, skeletal muscle has dem-
onstrated activation of DNA fragmentation and resultant apoptosis [58].
Certain signaling molecules in apoptotic pathways can either promote
or inhibit NF-κB activation [59,60]. A solid connection between muscle
apoptosis and sarcopenia has not yet been established, even though
some studies suggest a link in part because ﬁbers are multinucleated
[61–63].
2.5. Autophagy/lysosomal pathway
Autophagy is a process in which a cell's contents are degraded by
its own enzymes [64]. It occurs constitutively to maintain a dynamic
anabolic/catabolic balance within the cell. Even so, oxidative stress
[65,66] or extreme catabolic conditions [67,68] can upregulate au-
tophagy. mTOR is integrally involved in autophagy pathways [69],
yet in skeletal muscles, FoxO3 is the main inducer of autophagy
genes such as LC3 and Bnip3 [70]. Well-controlled FoxO3-induced
gene expression is a key to balanced autophagy.
2.6. Satellite cells
Satellite cells provide myoblasts for postnatal growth [71,72] and
are critical for skeletal muscle repair [73]. These cells are quiescent
until a stress (trauma, exercise) is imposed. There is controversy as
to whether satellite cells actually decrease in number with aging
[74–78]; however, their proliferative response and regenerative ca-
pacity to perturbation are reduced [79,80]. Evidence indicates that
reduced regenerative function is more likely a result of a less optimal
cellular environment than the cells being deﬁcient due to age
[81,82]. The reduced function in the satellite cell with aging is at
least coincidental with sarcopenia, and could possibly be a contribut-
ing factor of that process such that satellite cells in aged are less re-
sponsive to muscle damage.
Fig. 1. Protein synthesis and degradation pathways. Akt when activatedwill promote protein synthesis and inhibit protein degradation; inhibiting Akt will promote translocation of FoxO
to the nucleus to drive protein degradation. Degradation components: FoxO—forkhead box transcription factor, MAFbx—muscle atrophy F-box, MuRF—muscle ring ﬁnger protein, and
Smad 2/3—receptor-regulated transcription factors. Synthesis components: IGF-1—insulin-like growth factor-1, IRS—insulin receptor substrate, PI3K—phosphatidylinositol-3-kinase,
Akt—protein kinase B, mTOR—mammalian target of rapamycin, S6K— ribosomal p70 S6 kinase, 4EBP1 — 4E-binding protein, and MyoD—muscle differentiation protein.
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Numerous genetic mutant mouse models have been developed to
determine the biochemical and physiological pathways that inﬂuence
the processes of sarcopenia. We will examine some of the animals
that have assisted in our understanding of the roles of the various mol-
ecules and their contribution to the process of sarcopenia. The animal
models and affected pathways are summarized in Fig. 2.
3.1. IGF-1/PI3K/Akt pathway
Several laboratories have focused on the growth factors and their
downstream effectors in their evaluation of muscle function as it re-
lates to muscle loss.
3.1.1. IGF-1
Transgenic mice (MKR) [83] expressing mutated IGF-1 receptors in
skeletal muscle were exposed to functional overload [84] to observe
whether loading could promotemuscle growth in the absence of a func-
tional IGF-1 receptor. Hypertrophy occurredwith functional overload in
the presence and absence of normal IGF-1 receptors. IGF-1 typically ac-
tivates the PI3K/Akt pathway to induce protein synthesis and muscle
development. Signiﬁcant increases of Akt and p70S6K were demon-
strated in bothwild type andMKRmice. MKR and wild typemice dem-
onstrated equivalent gains in plantaris muscle weight following a
35-day loading regimen. These results indicate that muscle overload
can induce muscle growth through PI3K/Akt activation independent
of an operational IGF-1 receptor. We know that plasma IGF1 levels de-
crease with aging (in rodents and humans), thus skeletal muscle
growth in older animals may occur via both IGF-1-dependent and
-independent mechanisms [85].
Mavalli [86] and coworkers developed mice deﬁcient in GH recep-
tors or IGF-1 receptors in skeletal muscle. Both mutants displayed re-
duced muscle ﬁber number and cross-sectional area. The GH receptor
knockout mice had a lower proportion of type I gastrocnemius ﬁbersand a higher proportion of type II than wild type mice at 6 weeks of
age, yet ﬁber sizes were equivalent. Type II:type I ﬁber ratios were ap-
proximately 90:10 and 80:20 in GH receptor null andwild type, respec-
tively. At 16 weeks of age, ﬁber cross-sectional area was approximately
75% for both ﬁber types comparing GH receptor knockout to wild type,
with the difference continuing through 26 weeks of age. Fiber type ra-
tios were nearly the same between strains, 90:10, type II:type I. For
the IGF-1 receptor null mouse, a similar ﬁber type proportion was
present between the mutant and wild type at 6 weeks as was seen
with the GH receptor knockout but this difference remained at
16 weeks. Myoﬁbril cross-sectional areas were smaller in the IGF-1
receptor knockout than wild type at both 6 weeks and 16 weeks of
age. These models speak to the integral role of both GH and IGF-1 and
their associated receptors in the normal development of skeletalmuscle.
Several mouse models with disrupted GH/IGF-1 pathways are known
for their extended life spans [87]. The mechanism remains to be deter-
mined as to how this hormone deﬁciency promotes increased longevity.
Amesdwarf, Snell dwarf, Larondwarf, and “little”mice are either deﬁcient
in GH/IGF-1 or signaling is blocked at the cell membrane receptor and
thus lack the protein synthesis promotion possessed by animals with in-
tact GH/IGF-1 pathways. These animals pose a conundrum in that al-
though lacking a signiﬁcant component of the protein synthesis and
muscle growth pathway, a condition which should promote increased
frailty and therefore early death, these animals instead have extended
life spans. Further work is needed to determine how the GH/IGF-1 axis
plays an apparently vital part inmuscle growth, while its absence confers
another advantage to animal models, that of increased longevity.
3.1.2. IRS
Immediately downstream of insulin and IGF-1 is the effector IRS-1.
An IRS-1 knockout mouse exhibited continued PI3K/Akt signaling,
leading to the discovery of IRS-2, an alternate substrate for PI3K.
This insulin-resistant mouse demonstrated general reduced growth
by 30% to 60% compared to wild type [88,89]. Unfortunately, no spe-
ciﬁc information on muscle physiology has been reported at this time.
Fig. 2. Murine models and their respective pathway inﬂuences. MKR/GHRKO — IGF receptor mutant/growth hormone receptor knockout mice, IRS-2 KO — IRS-2 knockout mouse,
P85α mKO p85β−/− — PI3K knockout mouse, Akt1−/− & Akt2−/− — Akt knockout mice, Akt+/+ — Akt overexpression mouse, mTOR−/− — mTOR knockout mouse, Ku80 — Ku80
mutant mouse, p53— tumor suppressor protein 53, FoxO−/−— FoxO knockout mouse, FoxO+/+— FoxO overexpression mouse, MAFbx−/−—MAFbx knockout mouse, MAFbx+/+—
MAFbx overexpression mouse, MuRF1−/−/MuRF2+/+ — MuRF1 and MuRF2 double knockout mouse, and Mstn−/− — myostatin knockout mouse.
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skeletal muscle components have been published. However, these
mice weighed 90% of wild type mice at birth but displayed greater
than 50% reduction in PI3K activity upon insulin stimulation compared
to the PI3K activity in IRS-1 mice under comparable conditions [90].
Thus, both the IRS-1 and IRS-2 null mice contribute information regard-
ing the impact of growth factors such as insulin, GH and IGF-1 on mus-
cle development but provide less information on muscle loss.
3.1.3. PI3K
Several PI3K knockout mouse models have been developed. Most of
these mice exhibit normal growth; however, a null model was
established for the p85α/p55α/p50α and p85β regulatory subunits of
PI3K in heart and muscle, producing a mouse with reduced heart size
but essentially unchanged skeletal muscle size and morphology [91].
Exercise-induced cardiac hypertrophy was attenuated in the p85α
mKO p85β−/− mouse when exposed to 4 weeks of swim training;
however, the lack of PI3K in skeletal muscle did not adversely impact
this tissue's exercise capability in these animals. This particular knock-
out model focuses on the deletion of regulatory subunits of class IA
PI3K which impacted growth of cardiac muscle without inﬂuencing its
contractility. Skeletal muscle growth and performance were unaffected
by this regulatory subunit deletion. Based on this evidence, it appears
that other regulatory subunits of the PI3K pathway may have a greater
impact on sarcopenia, namely atrophy and strength decrement. Thus,
similar to the IRS-1 and IRS-2 knockout mice, some of these PI3K mu-
tants may not be as useful for studying sarcopenia.
3.1.4. Akt
The Akt1−/− (Akt 1null) mouse is a viable strain, yet it has a
shorter life span when exposed to gamma irradiation. This mouse
is smaller than wild type littermates; however, overall physiology
is minimally altered, including a nondiabetic phenotype [92]. The
Akt2 null mouse is indistinguishable in appearance at birth from
wild type mice but develops insulin resistance [93]. With regard to
skeletal muscle physiology, Goncalves and coworkers [94] founddecreased mass of extensor digitorum longus (EDL), gastrocnemius,
and quadriceps in Akt1−/− compared to wild type. The Akt2−/− also
demonstrated a mass decrease in EDL and gastrocnemius but a mass
increase in soleus when compared to the wild type. Mean
cross-sectional area of glycolytic EDL was reduced in both Akt1 null
and Akt2 null mice compared to wild type. Themore oxidative soleus
muscle cross-sectional area was not different between genotypes.
The proportion of type II soleus ﬁbers in the Akt1 null mouse was re-
duced but not in Akt2 null animals. Soleus type II ﬁber cross-sectional
areas in Akt1 null mice were smaller and that same ﬁber type number
was reduced when compared to wild type. Both of these Akt null mice
show promise as models to study sarcopenia with their tendency to
demonstrate muscle ﬁber size decrease. The Akt1 null mouse also ex-
hibits a decrease in type II ﬁber proportion that is consistent with
sarcopenia.
Akt1/Akt2 double-knockoutmice exhibit a severe growth deﬁciency
and skeletal muscle atrophy, resembling the IGF-1 receptor null mouse
[95]. Although phenotypically similar to IGF-1 receptor deﬁcient mice,
atrophy in the Akt double knockout is mainly due to reduced muscle
cell size while the IGF-1 deﬁcient mouse exhibits decreased muscle
cell number. In addition, the activity of mTOR, appears to be
downregulated in the Akt double knock out [96]. However, since this
mutant dies soon after birth, it is not useful in the study of sarcopenia.3.1.5. Akt overexpression
In contrast to the KOmutants, the overexpression of constitutive-
ly active Akt in vitro leads to phosphorylation of p70S6K, PHAS-1/
4E-BP1 and to marked hypertrophy of myotubes [25]. Denervated
muscle ﬁbers in Akt transgenic mice were signiﬁcantly larger than
denervated ﬁbers of wild type mice and were of a ﬁber size distribu-
tion representative of mice without nerve injury after 7 days. This
experiment demonstrates that Akt overexpression increases muscle
atrophy resistance and maintenance of ﬁber size distribution follow-
ing denervation [29]. This particular model may be useful in
researching sarcopenia by aiding in the study of downstream events
of Akt overexpression.
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A viablemTOR null mouse has been developed that exhibits reduced
fast twitchmuscle growth resulting in stunted postnatal growth [97]. At
6 weeks of age, type II muscles such as gastrocnemius, tibialis anterior,
and plantaris experienced reduced weights compared to wild type
mice. The cross-sectional area of tibialis anterior was also reduced com-
pared to wild type mice while both cross-sectional area and weight of
soleus were increased (when normalized to body weight). mTOR null
mice showed dystrophic features that were especially prominent in ox-
idative ﬁbers, possibly explaining the soleus size increases. Fiber num-
ber differences between strains were not evident at 6 weeks. Since
the skeletal muscle morphological changes in the mTOR null mouse re-
semble more the changes seen in themyopathy of muscular dystrophy,
thismutantmay not servewell as a sarcopeniamodel. In addition, these
animals exhibit shortened life spans [97].
3.3. FoxO
Transgenic mice overexpressing FoxO1 weighed less than wild type
mice and have reduced comparativemusclemass [98].Microarray anal-
ysis discovered decreased gene expression of structural proteins of slow
twitch muscle. At 3 months of age there was a marked decrease in the
size of type I and II ﬁbers and a signiﬁcant decrease in the number of
type I ﬁbers when compared to wild type mice. Gene expression of ca-
thepsin L, a lysosomal proteinase that is typically upregulated with
muscle atrophy, was elevated. The FoxO1 transgenic also displayed re-
duced spontaneous locomotor activity at 9 to 10 weeks of age. The de-
scribed characteristics in thismurinemodel are indicative of sarcopenia.
However, the propensity for selectively-reduced type I muscle ﬁber
gene expression is counter to that seen in sarcopenia, in which type I
ﬁber function is maintained better than type II [21].
FoxO1nullmice exhibit a reduction in slow twitch ﬁber formation in
soleus muscle while the predominantly type II ﬁber plantaris muscle
composition was unchanged [99]. Both male and female FoxO1 mice
demonstrated reduced endurance compared towild type, a ﬁnding con-
sistent with the reduction in type I ﬁber content. This model, similar to
the FoxO1 transgenic mouse, displays a reduction in slow ﬁber content
while not affecting type IIﬁber composition. This characteristic does not
parallel the fast-to-slow ﬁber transition observed in sarcopenia. Unfor-
tunately, this study did not address muscle size, so the contribution of
this mutant to our understanding of sarcopenia is unclear.
3.4. MuRF1 and MAFbx
Two factors shown to be speciﬁcally involved in muscle atrophy are
MuRF1 andMAFbx. Mice null for either MuRF1 or MAFbx resistedmus-
cle atrophy following sciatic denervation, showing 36% and 56% gas-
trocnemius muscle weight sparing at 14 days following injury,
respectively, with most of the loss occurring by the 7-day mark [100].
MAFbx+/+ mice continued to lose muscle mass between 7 and
14 days. MAFbx null mice exhibited larger muscle ﬁbers than the wild
type in the affected muscles. Interestingly, these atrogene knockout
mice had normal muscle size and morphology as well as normal viabil-
ity, fertility and longevity before sciatic nerve denervation.
Double MuRF1 and MuRF2 knockouts individually are healthy,
normal-appearing animals [101]. Double knockout (dKO) MuRF1/
MuRF2 (all four MuRF1 and MuRF2 alleles inactivated) mice develop
skeletal muscle hypertrophy stemming from individual ﬁber growth,
resulting in a 38% increase in quadriceps to body weight ratios com-
pared to wild type. By contrast, either allele knockout produced 11%
to 17% increase in the quadriceps to body weight ratios. The double
allele inactivation did not inﬂuence degradative entities, such as
MAFbx/atrogin1 expression. Mutant mice that underexpress the E3
ubiquitin ligases are good models for atrophy following denervation
and possibly for disuse atrophy; however, their utility may be limitedas sarcopenic models, because muscle loss from sarcopenia is limited
[102].
3.5. Myostatin
Some rodentmodels of neuromuscular disease have beneﬁtted from
the application of myostatin neutralizing antibodies with increased
muscle ﬁber size (however not enhanced muscle function) [103,104].
Myostatin gene knockout in mice (Mstn−/−) increased muscle mass
by way of both hypertrophy and hyperplasia [43]. Antiapoptotic factor
expression increased in these Mstn−/− mice as well [105]. The reduc-
tion in myostatin expression in Mstn−/− mice increased both satellite
cell number and type IIB/X ﬁber cross-sectional area in tibialis anterior
muscles with improved regenerative potential [47]. Satellite cell activa-
tion, also an indicator of regenerative capability, was reduced in both
old Mstn−/− and wild type mice. Young Mstn−/−mice had higher sat-
ellite cell number and activation than young wild type mice. Young
Mstn−/−mice also had a higher percentage of glycolytic muscle ﬁbers
while the older Mstn−/− mice had more oxidative ﬁbers. However,
McMahon and coworkers [106] found Mstn−/− mice to be more sus-
ceptible to atrophy from unloading. Although myostatin's role in
sarcopenia is debated, with myostatin mRNA expression ranging from
decreased [107] to unchanged [108] to increased [109] in aging rodent
studies, the retention of muscle mass in the aged myostatin knockout
mouse supports the consideration ofmyostatin as an inﬂuence onmus-
cle mass and the Mstn−/− mouse as a model for study of age-related
muscle loss [110].
Elevated myostatin levels in mice by injection induced signiﬁcant
muscle mass loss [111], yet myostatin overexpression in adult mice
inhibited Akt/mTOR signaling without the promotion of atrogene ex-
pression [112,113], therefore this pathway appears to bemore involved
in limiting hypertrophy than promoting atrophy [63]. Myostatin's role,
however, in the atrophy of unloading is conﬂicted, with studies
reporting both increased and unaltered [114,115] myostatin expres-
sion. Those studies whose results yielded increased myostatin expres-
sion found myostatin changes primarily within fast muscle types
[116,117].
In a cachexia model, increased myostatin expression did result in
protein degradation via FoxO1 expression [118]. These unloading and
cachexia models suggest that myostatin does play a role in atrophy
under certain conditions [63].
3.6. Apoptosis
The expression of muscle apoptosis genes (caspase-3, caspase-9,
bax, and Smac/DIABLO) are decreased in the female GHRKO (growth
hormone receptor/binding protein knockout) mouse skeletal muscle
when compared to wild type mice. This mouse is known for its longev-
ity due to its disrupted growth hormone signaling pathway. Other ad-
vantages these mice exhibit include enhanced oxidative stress
handling [119–121] and reduced incidence of neoplasms [122]. Re-
duced apoptosis gene and protein expression may also contribute to
the extension of life span in this animal. Caloric restriction is also
known for increasing life span [123]; however, the addition of caloric
restriction in this study did not alter the expression of apoptotic genes
[124]. Although reduced apoptosis typically increases incidence of neo-
plasms [125], mice with decreased circulating IGF-1 demonstrate re-
duced incidence and/or delayed development of tumors [122,126].
Since research suggests that apoptosis in skeletal muscle is linked to
sarcopenia [61,127] and since lack of caspase-3 has shown a protective
effect against skeletal muscle atrophy from denervation [128], this
model could serve as a good candidate for sarcopenia studies. However,
as mentioned earlier, atrophy from denervation follows a different bio-
chemical pathway than sarcopenia. Also, skeletalmuscle growth via the
IGF-1/PI3K/Akt pathway is likely impacted in this knockout, therefore, it
would be important to distinguish whether any resemblance to
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the decrease in growth hormone signaling.
The Mstn−/− (myostatin null) mice described earlier exhibit in-
creased expression of antiapoptotic genes [105]. However, the signif-
icance of a relationship between apoptotic proteins and muscle
growth remains to be understood. Skeletal muscle appears able to de-
fend against apoptosis with its high level of endogenous inhibitors
[129], with apoptotic events promoted with the stress of exercise
and muscle pathology [130–132].
Pathways that are key to the protein synthesis critical for muscle
growth arewell established. Someof themodels discussed demonstrate
a perturbation of those pathways; yet they do not always have a strong
connection to an aging inﬂuence on muscle mass loss or ﬁber composi-
tion change. As these pathways do have an inﬂuence onmuscle growth,
their continued inclusion in research in aging will likely give additional
insights into the process behind muscle loss with age.
3.7. Accelerated aging models
Investigations focused on aging have generated speciﬁc informa-
tion on muscle function over the life span and have contributed to
our understanding of muscle loss. Several mouse models with an
accelerated aging phenotype have been developed, enabling a
“fast-forward” observation of aging's inﬂuence onmuscle physiology
and form. Animals identiﬁed as accelerated models of aging afford us
the convenience of examining the effects of aging earlier in the life of
the animal, shortening the requisite wait for senescence. However,
accelerated aging models do not always demonstrate characteristics
typical of aging for the animal studied. The genetic manipulation
performed in developing these animals often affects the physiology
of other body systems, inﬂuencing results in the tissues studied. Sev-
eral of these examples are summarized in Fig. 3. The Zmpste24−/−
mouse, mimicking Hutchinson–Gilford progeria syndrome, stops
growing at 5 weeks of age and has a median survival age of
123 days [133,134]. Greising and coworkers [133] compared muscle
characteristics between these mice with a mutation in the gene
encoding metalloproteinase for lamin A maturation against litter-
mates without the mutation. Very late in life for the Zmpste24−/−
mouse (20 weeks), the homozygous knockout exhibited less physi-
cal activity and had less than half the body mass of the wild type
mouse. The Zmpste24−/− mice displayed reduced grip strength and
whole body tension when controlled for body size. The knockout
demonstrated progressive ankle range of motion losses after
5 weeks of age while the wild type retained its ankle mobility. Pas-
sive ankle torques in the Zmpste24−/−mice were high, indicating in-
creased joint stiffness. The collagen content of leg muscles was
45%–72% higher in the Zmpste24−/−mouse, possibly explaining the in-
creased joint and muscle stiffness in that strain. Anterior leg mus-
cles (extensor hallucis longus, tibialis anterior, extensor digitorum
longus) were weaker in the knockout mouse, while posterior
hindlimb muscles exhibited equivalent strength between strains.
Ex vivo strength testing (maximal isometric tetanic force) of these
same muscle groups showed the same results. Actual muscle mass
of hind limbs across strains was comparable after adjusting for
body mass. Serum creatine kinase levels were similar between
strains; higher levels would have indicated muscle injury. Although
the mean cross-sectional area of soleus ﬁbers was not different be-
tween strains, there was a different distribution of soleus ﬁber sizes,
with Zmpste24−/− having more small and large ﬁber sizes. A sim-
ilar percentage of soleus ﬁber types were observed in both strains.
Zmpste24−/− mice had more nuclei, yet no difference was seen in the
percentage of ﬁbers with centrally- (indicative of dysfunction) ver-
sus extracellularly-positioned nuclei. Extensor digitorum longus ﬁ-
bers were smaller in the Zmpste24−/− mice and had more type IIa
and fewer type IIb ﬁbers. Histologically, in general, the Zmpste24−/−
had normal, healthy appearing muscles, with no signs of dystrophyor degeneration. The general phenotype is one of impaired neuro-
muscular performance and selective muscle weakness when com-
pared to the Zmpste24+/+ littermates, which are characteristics
matching those of aged mice. How well this model represents accel-
erated aging is controversial, as humans with progeria exhibit some
aspects of rapid aging but not others [135].
Another model of aging is the senescence-accelerated mouse
(SAM) [136]. Lineages of this mouse include 14 senescence-prone in-
bred strains and 4 senescence-resistant inbred strains, with mean
life spans of 9.7 and 13.3 months, respectively [137]. Characteristic
aging features in the senescence-prone mice initially include abnor-
mal behavior, skin lesions, cataracts, elevated amyloidosis, and in-
creased spinal lordokyphosis [137]. Other pathologies simulating
aging, such as learning and memory deﬁcits, degenerative joint dis-
ease, osteoporosis, tumors, and kidney dysfunction, have also been
discovered [138]. Research suggesting that SAMP6 [139] and
SAMP8 [140] strains are appropriate as aging muscle models investi-
gated ﬁber size and quadriceps tubular aggregate accumulation,
respectively. Derave and coworkers [136] examined several proper-
ties of muscle physiology, including muscle metabolites, muscle
mass, contractile properties, force generation, fatigability, and ﬁber
size and distribution among 2 strains of senescent-accelerated
(SAMP6, SAMP8) and 1 strain of senescent-resistant (SAMR1) mice.
All mice were studied at 10, 25, and 60 weeks of age. Both accelerat-
ed aging models displayed reduced muscle contractility, decreased
ﬁber size and muscle phosphocreatine levels with aging. However,
SAMP8 exhibited the features most demonstrative of accelerated
muscle aging with greater reduction in muscle phosphocreatine
levels, muscle mass and contractility, and type-II ﬁber size atrophy,
with aging features developing earlier and at a faster rate than
SAMP6 or SAMR1. Muscle ﬁber composition in soleus showed a shift
toward more type I ﬁbers over time in both SAMP6 and SAMP8;
however the difference wasn't signiﬁcant. No ﬁber size or type distri-
bution change was signiﬁcant in the extensor digitorum longus of ei-
ther SAMP6 or SAMP8. These ﬁndings suggest that the SAMP8mouse
soleus is a reasonable model for muscular aging studies.
The Ku80+/−mouse is an animal that displays acceleratedmuscle
aging in the presence of normal postnatal growth. The Ku80 knock-
out mouse exhibits both reduced postnatal growth and severe pro-
geria. The Ku80 heterodimer assists in the repair of DNA double
strand breaks and helps with telomere stability [141]. Didier and col-
leagues [142] found that the Ku80−/− mice displayed an increased
proportion of slow ﬁbers with a decreased proportion of fast ﬁbers
in soleus muscle compared to young Ku80+/+ mice. Ku80+/− animals
also demonstrated a size reduction in all soleus ﬁber types as compared
to Ku80+/+. The Ku80−/− mouse is smaller than the Ku80+/+ mouse
[143] and smaller type I and II ﬁbers were found in the knockout
mouse [142]. The Ku80+/− mouse is the same size as the Ku80+/+
mouse; however, both type I and II soleus ﬁbers are also smaller than
those of the Ku80+/+ mice, so in this model it appears that the ﬁber
size is not associated with body size. Following serial injuries, both
Ku80+/− and Ku80−/−mice exhibited reduced tibialis anterior muscle
regeneration potential and also reduced stem-cell self-renewal com-
pared to the homozygous wild type. At birth, Ku80 wild type and
Ku80 null mice had equal numbers of satellite cells while at 15 days
the Ku80−/− mouse had signiﬁcantly fewer. Satellite cell numbers for
heterozygous and wild type were not different at those two life points.
Ku80−/− mice exhibited muscle stem cell DNA damage while no DNA
damage was detected in Ku80+/− or in wild type young and old mice.
Crossing Ku80+/− mice on a p53 null background recovered the wild
typemixedﬁber (I/IIa) proportion that is reduced in Ku80heterozygous
animals, a picture of accelerated aging. Although this cross restored a
more “youthful” ﬁber composition mix, the regenerative capacity typi-
cal of wild type muscle was still absent in the Ku80+/−.
Another model of accelerated aging which mimics sarcopenia is
the POLG mouse, a homozygous knock-in mouse with impaired
Fig. 3. Accelerated aging mouse models and their respective phenotypes.
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This mouse exhibits increased mtDNA point mutations and deleted
mtDNA. Its reduced life span (median survival less than 50% of wild
type) and physical traits such as spinal kyphosis, osteoporosis, and al-
opecia suggest a causal relationship between the mtDNA mutations
and premature aging. Although ﬁnding no evidence of elevated oxi-
dative stress in the presence of these mutations, Kujoth and col-
leagues [145] discovered increased induction of apoptosis by
examining caspase-3 activation in several tissues at earlier ages. No-
tably, brain and skeletal muscle (both postmitotic tissues) apoptosis
induction was not elevated to the same extent at earlier ages as in tis-
sues with rapid cellular turnover, suggesting a resistance to induction
of apoptosis. POLG mice exhibited a 10% decrease in weight in both
gastrocnemius and quadriceps muscles at 9 months of age, while at
3 months of age respective muscle weights were comparable. The evi-
dence for muscle loss in this prematurely aging animal over a
6-month period indicates that it may show promise as a useful model
of sarcopenia in the presence of increased mtDNA mutation load.
A mouse model has been developed that exhibits the frailty seen in
the elderly [146]. The “frail” mouse is characterized by a homozygous
deletion of the IL-10 gene, an anti-inﬂammatory cytokine. The absence
of this interleukin promotes the expression of NF-κB inﬂammatory me-
diators. To mimic human frailty, typical characteristics of muscle weak-
ness, inﬂammation, decreased physical function, and overall reduced
activity should appear later in life. Signs of frailty in the IL-10tm/tm
mouse such as decreased strength and slowed weight gain appeared
after 10 months. Old IL-10tm/tm mice (50 weeks) had higher levels of
serum IL-6 than age-matched wild type mice. Levels of IL-6, known to
promote frailty and disease in older humans, were different between
young and old frail mice but not between young and old wild type
mice. Upregulated genes in the IL-10tm/tm mice included those known
for apoptosis and mitochondrial function. Downregulated genes in the
frail mouse were those involved in protein transport and regulation of
cell growth and maintenance. This particular model of aging appears
to reﬂect well those features of frailty; however, there is less support
for the involvement of inﬂammation in sarcopenia. Therefore, the frail
mouse is useful for the study of muscle wasting in the presence of in-
ﬂammation but would be limited as a model of sarcopenia, which in-
volves the loss of muscle mass without the inﬂuence of disease or
inﬂammation.Fewer models of cachexia have been created solely for the study of
muscle atrophy but each may be important in determining the roles
of other factors involved. The ApcMin/+ mouse is a genetic model of
colon cancer, triggered by a mutation of the polyposis coli (Apc) gene
[147], leading to intestinal polyps and eventually tumor formation
[148]. This mouse has also become a model of cachexia, with a signiﬁ-
cant loss of muscle and fat tissue by 6 months of age [148,149]. At
3 months of age ApcMin/+ and C57BL/6 mice have similar body weights
and gastrocnemius and soleus sizes; however by 6 months, gastrocne-
mius and soleus muscle weights fall by 45% and 25%, respectively,
with soleus muscle mean ﬁber cross-sectional area decreasing by 24%.
Nuclei number and location (myoﬁber, extracellular matrix, or central-
ized) in the soleus indicate that there is considerable degeneration and
regeneration in the more highly oxidative muscle. IL-6 is a cytokine
known for its cachectic impact, and the ApcMin/+ mouse exhibits elevat-
ed levels of circulating IL-6 when compared to age-matched wild type
mice. An ApcMin/+/IL-6−/− was created and showed that at 26 weeks
of age, muscle mass was similar to wild type (C57BL/6), as opposed to
the observation in the ApcMin/+ strain where a signiﬁcant loss of gas-
trocnemius weight was detected. Gastrocnemius mass was reduced by
23% with IL-6 overexpression and 32% in ApcMin/+ and ApcMin/+/
IL-6−/− mice, respectively. Wild type mice and ApcMin/+ mice without
polyp burden did not experience cachexia or muscle mass loss in the
presence of IL-6 overexpression. IL-6 levels may increase tumor burden
and the tumor burden appears to promote the cachexia. However,
Baltgavis and coworkers [150] demonstrated that muscle mass de-
creased even with low levels of IL-6 while others associate high IL-6
levels with muscle wasting [151,152]. Although MuRF-1 expression
did not change with age in ApcMin/+ mice, MAFbx expression was in-
creased 10-fold as circulating IL-6 increased. MAFbx protein levels in-
creased as well [153]. With IL-6 overexpression, MAFbx expression
and protein levels also increased, while MuRF-1 expression remained
unchanged [153]. These investigators suggested that an interaction be-
tween tumors and IL-6 levels promotes an environment favorable to the
degradation of skeletal muscle [150]. Exercise which is often used to
counteract muscle atrophy of various origins was found to reduce the
muscle wasting effects accompanying IL-6 presence, even IL-6
overexpression, in conditions that promote cachexia [154,155].
The MIPKO (muscle-speciﬁc inositide phosphatase knock out)
mouse is an animal lacking muscle-speciﬁc inositide phosphatase,
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tation–contraction coupling in skeletal muscle [156]. This animal
demonstrates several characteristics consistent with premature
aging relative to muscle structure and function [157]. The MIPKO is
spontaneously less active and reaches exhaustion earlier than simi-
larly aged wild type littermates. Body weight and muscle mass loss,
including reduced extensor digitorum longus ﬁber cross-sectional
area, is apparent by 18 months of age compared to the wild type
[156,157]. Contractile force generation was reduced in both old
wild type and mature and old MIPKO mice compared to mature
wild type mice. Ca2+ homeostasis in muscle was altered, both
the old wild type and mature MIPKO displayed dysfunctional
Ca2+ resting levels, Ca2+ release, and Ca2+ transient recovery.
In general, similarities between muscle morphology and function
were found between mature (12–14 month) MIPKO and old wild
type (22–24 month) mice, demonstrating an accelerated aging mus-
cle phenotype in the MIPKO mouse. This model focuses on the phys-
ical dysfunction elements of sarcopenia. Thus, we await further
studies in this animal to examine the muscle morphology changes
and atrophy pathways more closely.
The models listed above are all examples of constitutive inﬂuences
of genetic expression on pathways and resultant phenotypes. As these
animals assume their knockout or transgenic genotype, they will expe-
rience that inﬂuence from the time of conception through development
to the end of life. Sarcopenia is a postmaturational phenomenon whose
process could be altered and therefore be inaccurately represented
when inﬂuenced by these constitutive models. An inducible model ex-
ists inwhichmuscle gene expression can be initiated after attainingma-
turity [158]. The HSA-MCM mouse allows for limb and craniofacial
skeletal muscle-speciﬁc expression of a protein to occur only upon the
administration of a tamoxifen trigger. This type ofmodel enables the re-
searcher to assess protein expression at any point along the life span,
minimizing confounding inﬂuences that genetic manipulation might
elicit when spanning great time periods or crossing developmental
transition points.
4. Conclusion
Sarcopenia, as described by the European Working Group on
Sarcopenia in 2010, is a progressive and generalized loss of both skeletal
muscle mass and function [159]. Evans [160] adds that sarcopenia is
age-related and is a different condition than cachexia. Although atrophy
is considered the source of the resultant functional loss, some believe
that the loss of muscle function cannot be fully explained by muscle at-
rophy alone [161–163]. In any case, the phenomenon of sarcopenia has
devastating ramiﬁcations for senior citizens as they experience the loss
ofmusclemass and strength to the point atwhich they can no longer be
independent.
The murine models of muscle loss described above provide some
insight into their utility to better understand this process. We
reviewed models that exert an inﬂuence along the IGF-1/PI3K/Akt
pathway, a biochemical pathway known to play a large role in the
regulation of skeletal muscle growth [164]. We have also examined
models whose overall phenotype is that of an accelerated aging ani-
mal, observing whether the aging phenotype has manifested itself in
the skeletal muscle system as decreased mass, decreased strength,
and ﬁber type composition transfer, typical of sarcopenia. The de-
scribed models have provided useful, yet incomplete, insight into
the sarcopenia process. Some of the mutants have very short lives
and, therefore, do not provide an animal that can develop and ad-
vance through life to old age. Some of the animals impact muscle
growth; however, the muscle characteristics such as ﬁber type com-
position or type I or type II size may not resemble that of sarcopenic
muscle. Several of the models listed have collected limited data rela-
tive to physical muscle characteristics that deﬁne sarcopenia. Impor-
tant information relating to sarcopenia pathways has been extracted,however, similar measures have not been performed across these
model systems, creating difﬁculty in evaluating their appropriate-
ness for studying various causes of skeletal muscle atrophy, whether
it is disuse, cachexia, or sarcopenia. Sarcopenia continues to interfere
with health and is becoming a larger and larger socioeconomic bur-
den to society. Identifying or creating valid models of sarcopenia
will be an important endeavor in reducing its negative impact.
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